DXCM DEXCOM INC
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1093557 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY13.0%
TTM net income YoY37.5%
TTM EPS YoY41.1%
Revenue 3-yr CAGR14.5%
Net income 3-yr CAGR38.0%
Margins
Gross margin63.4%
Operating margin24.0%
Net margin19.4%
FCF margin21.5%
EBITDA margin29.4%
Returns
ROE37.7%
ROA14.4%
ROIC (approx.)78.0%
Asset turnover0.74x
Leverage & solvency
Liabilities / assets59.4%
Debt / equity0.00x
Current ratio1.74x
Interest coverage91.33x
Cash quality & payout
Operating cash flow / net income1.43x
Accruals ratio-6.2%
Payout ratio—
Capex / revenue6.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.34B | $1.31B | $1.19B | $1.26B | $1.21B | $1.16B | $1.04B | $1.11B |
| Cost of revenue | $480.10M | $478.40M | $441.60M | $466.90M | $477.90M | $468.30M | $447.00M | $457.70M |
| Gross profit | $864.40M | $830.00M | $750.30M | $792.70M | $731.40M | $688.80M | $589.00M | $655.80M |
| R&D expense | $161.60M | $153.00M | $145.30M | $148.20M | $157.50M | $148.20M | $145.20M | $139.50M |
| SG&A expense | $375.60M | $358.70M | $349.70M | $321.50M | $331.40M | $328.00M | $310.10M | $327.40M |
| Operating income | $327.20M | $318.30M | $255.30M | $323.00M | $242.50M | $212.60M | $133.70M | $188.90M |
| Interest expense | $3.10M | $3.00M | $3.10M | $4.20M | $4.70M | $4.70M | $4.70M | $4.90M |
| Pretax income | $334.70M | $317.50M | $269.50M | $340.70M | $352.30M | $241.10M | $154.30M | $211.30M |
| Income tax | $59.60M | $68.40M | $70.00M | $73.40M | $68.50M | $61.30M | $48.90M | $59.60M |
| Net income | $275.10M | $249.10M | $199.50M | $267.30M | $283.80M | $179.80M | $105.40M | $151.70M |
| EBITDA | $401.70M | $386.50M | $322.40M | $388.20M | $306.10M | $275.60M | $193.70M | $246.70M |
| EPS (basic) | 0.73 | 0.65 | 0.52 | — | 0.73 | 0.46 | 0.27 | — |
| EPS (diluted) | 0.72 | 0.64 | 0.51 | — | 0.70 | 0.45 | 0.27 | — |
| Weighted avg. shares (diluted) | 383.50M | 390.10M | 393.60M | — | 407.40M | 408.20M | 407.50M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $961.40M | $1.10B | $1.12B | $917.70M | $1.84B | $1.16B | $904.90M | $607.30M |
| Short-term investments | — | — | — | — | — | — | $1.56B | $1.73B |
| Receivables | $1.19B | $1.26B | $1.09B | $1.22B | $1.11B | $1.35B | $1.16B | $1.01B |
| Inventory | $770.70M | $726.40M | $693.60M | $629.10M | $604.10M | $570.70M | $538.20M | $542.60M |
| Current assets | $3.92B | $4.09B | $4.33B | $4.03B | $5.22B | $5.03B | $4.55B | $4.30B |
| PP&E, net | $1.54B | $1.58B | $1.56B | $1.56B | $1.47B | $1.46B | $1.36B | $1.34B |
| Goodwill | $24.00M | $24.10M | $24.20M | $24.20M | $24.10M | $24.10M | $23.10M | $22.80M |
| Intangibles | $89.40M | $101.60M | $62.60M | $70.80M | $79.00M | $87.20M | $95.20M | $103.40M |
| Total assets | $6.24B | $6.46B | $6.63B | $6.34B | $7.50B | $7.33B | $6.75B | $6.48B |
| Current liabilities | $2.25B | $2.36B | $2.22B | $2.14B | $3.34B | $3.31B | $3.04B | $2.93B |
| Total liabilities | $3.70B | $3.83B | $3.68B | $3.59B | $4.77B | $4.75B | $4.49B | $4.38B |
| Shareholders' equity | $2.54B | $2.62B | $2.96B | $2.75B | $2.73B | $2.57B | $2.27B | $2.10B |
| Shares outstanding | 373.00M | 377.40M | 385.90M | 384.80M | 390.00M | 392.20M | 392.10M | 390.70M |
| Cash flow statement | ||||||||
| Operating cash flow | $325.60M | $269.20M | $525.60M | $294.00M | $659.90M | $303.00M | $183.80M | $301.40M |
| Capital expenditure | $52.90M | $84.70M | $76.60M | $101.90M | $80.50M | $94.10M | $87.00M | $124.60M |
| Free cash flow | $272.70M | $184.50M | $449.00M | $192.10M | $579.40M | $208.90M | $96.80M | $176.80M |
| Investing cash flow | -$76.70M | $329.80M | -$298.50M | $306.60M | $192.80M | -$63.60M | $100.20M | -$303.70M |
| Financing cash flow | -$391.50M | -$607.30M | -$25.00M | -$1.52B | -$175.00M | -$1.70M | $12.50M | -$1.60M |
| Depreciation & amortization | $74.50M | $68.20M | $67.10M | $65.20M | $63.60M | $63.00M | $60.00M | $57.80M |
| Stock-based compensation | $36.80M | $39.00M | $43.30M | $35.00M | $45.10M | $45.30M | $34.20M | $43.30M |
| Share buybacks | $400.00M | — | — | $312.80M | $187.20M | — | — | $0 |
Free plan shows the latest 8 periods; Pro shows all 67 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.